← Back to headlines
Truist Increases Price Target for Immunovant While Maintaining Hold Rating
Truist has raised its price target for Immunovant, Inc. (IMVT) but has chosen to maintain a "Hold" rating on the stock.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
